Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment

Constitutively active mutated BRAF kinase occurs in more than 40% of patients suffering from melanoma. To block its activity, a specific inhibitor, vemurafenib, is applied as a therapy. Unfortunately, patients develop resistance to this drug rather quickly. Previously, we demonstrated that pairs of...

Descripción completa

Detalles Bibliográficos
Autores principales: Dratkiewicz, Ewelina, Simiczyjew, Aleksandra, Pietraszek-Gremplewicz, Katarzyna, Mazurkiewicz, Justyna, Nowak, Dorota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981576/
https://www.ncbi.nlm.nih.gov/pubmed/31877948
http://dx.doi.org/10.3390/ijms21010113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981576/
https://www.ncbi.nlm.nih.gov/pubmed/31877948
http://dx.doi.org/10.3390/ijms21010113

Ejemplares similares